Biocytogen Pharmaceuticals (Beijing) Co., Ltd. published its 2025 Environmental, Social and Governance (ESG) report, detailing financial and non-financial performance across its A- and H-share operations.
Financial highlights show operating revenue of RMB 1.38 billion, total assets of RMB 3.72 billion and R&D expenditure of RMB 0.44 billion—equivalent to 31.77% of total spending. The company has now signed over 350 drug co-development, licensing or transfer agreements, with more than 150 sealed during 2025.
The workforce reached 1,443 employees, 71% of whom are female; R&D staff accounted for 31.19%. Training coverage and safety-training coverage both stood at 100%, while the overall employee turnover rate was 15.2%. No incidents of child or forced labour were identified.
On governance, Biocytogen’s nine-member board (44% female) met ten times with full attendance. Anti-corruption training covered all staff and directors, and no corruption cases were reported.
Environmental metrics reveal total Scope 1 emissions of 112.42 tCO₂e and Scope 2 emissions of 17,305.24 tCO₂e, giving combined emissions of 17,417.66 tCO₂e. Electricity usage reached 61,783.41 MWh, while solar/PV generation contributed 39,937.80 MWh. Water consumption was 85,757 tonnes. The report records zero environmental penalties and a 100% compliant hazardous-waste disposal rate (62.29 tonnes).
Operational quality initiatives included zero product recalls, a 100% product inspection pass rate and full resolution of 96 customer complaints. The company maintained ISO-aligned laboratory and biosafety controls, conducted comprehensive environmental impact assessments and carried out annual radiation and fire-safety drills.
Looking ahead, Biocytogen plans to deepen low-carbon R&D, expand employee incentives and continue refining board-level oversight of climate-related risks.
Comments